Fitzgibbon J E, Farnham A E, Sperber S J, Kim H, Dubin D T
Department of Molecular Genetics and Microbiology, University of Medicine and Denstistry of New Jersey-Robert Wood Johnson Medical School, Piscataway 08854.
J Virol. 1993 Dec;67(12):7271-5. doi: 10.1128/JVI.67.12.7271-7275.1993.
Multiple mutations were found in the human immunodeficiency virus pol gene following treatment of an AIDS patient with antiretroviral drugs. After approximately 2.5 years of monthly alternating therapy with 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC), most of the pol sequences amplified from the patient's peripheral blood mononuclear cell DNA contained known AZT resistance mutations at codons 41, 67, and 215 and a putative ddC resistance mutation at codon 69 as well as other novel mutations. These mutations persisted for 6 months after the patient was switched to 2',3'-dideoxyinosine monotherapy. Mutations known to be associated with 2',3'-dideoxyinosine resistance did not occur during this time. Antiviral susceptibility testing of point mutants, introduced into the genetic background of laboratory strain NL4-3, showed that the codon 41 mutation antagonized ddC resistance when present with the codon 69 mutation. However, this antagonism was not found with a chimeric mutant containing the patient's pol gene sequence from codons 25 to 218, implying that other mutations compensated for the antagonism. Thus, alternating therapy with AZT and ddC resulted in the selection of viruses resistant to both drugs.
在一名艾滋病患者接受抗逆转录病毒药物治疗后,在人类免疫缺陷病毒pol基因中发现了多个突变。在用3'-叠氮-3'-脱氧胸苷(AZT)和2',3'-双脱氧胞苷(ddC)进行每月交替治疗约2.5年后,从患者外周血单核细胞DNA中扩增出的大多数pol序列在密码子41、67和215处含有已知的AZT耐药突变,在密码子69处含有一个推定的ddC耐药突变以及其他新突变。在患者改用2',3'-双脱氧肌苷单一疗法后,这些突变持续了6个月。在此期间未出现已知与2',3'-双脱氧肌苷耐药相关的突变。对引入实验室菌株NL4-3遗传背景的点突变体进行抗病毒药敏试验表明,当密码子41突变与密码子69突变同时存在时,该突变拮抗ddC耐药性。然而,在一个包含患者从密码子25到218的pol基因序列的嵌合突变体中未发现这种拮抗作用,这意味着其他突变补偿了这种拮抗作用。因此,AZT和ddC交替治疗导致了对两种药物均耐药的病毒的产生。